Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter 2013
Date:8/6/2013

s added a new drug to its pipeline, ISIS-ANGTL3Rx, for the treatment of hyperlipidemia.

Corporate Highlights

  • Isis successfully completed a public offering of common stock raising $173.2 million in net proceeds.  Isis plans to use the proceeds from this offering to pursue Phase 3 development of ISIS-APOCIIIRx, retain additional drugs longer in development and advance the rest of its pipeline. 
  • Isis added Breaux Castleman, a senior executive with extensive business experience, to its Board of Directors. 
  • Isis received $6 million from AstraZeneca related to the continuation of the research collaboration between Isis and AstraZeneca to discover and develop novel antisense drugs to treat cancer.
  • Isis formed a new alliance with Roche to discover and develop antisense drugs to treat Huntington's disease.
  • Isis received a $30 million upfront payment and is eligible to receive up to $362 million in a license fee, pre-licensing and post-licensing milestone payments, including up to $80 million in commercial milestones.
  • In addition, Isis is eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed plus up to $50 million in commercial milestones if a drug using Roche's proprietary brain shuttle technology is successfully commercialized.
  • Isis is also eligible to receive tiered royalties on sales of drugs arising from the alliance. 
  • Conference Call
    At 11:30 a.m. Eastern Time today, August 6, 2013, Isis will conduct a live webcast conference call to discuss this earnings release and related activities.  Interested parties may listen to the call by dialing 866-652-5200, or access the webcast at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.

    ABOUT ISIS PHARMACEUTICALS, INC.
    Isis is exploitin
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. CVS Caremark Reports Record Second Quarter Results
    2. BioLineRx Reports Second Quarter 2013 Results
    3. Regeneron Reports Second Quarter 2013 Financial and Operating Results
    4. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
    5. Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis
    6. Landauer, Inc. Reports Fiscal 2013 Third Quarter Results
    7. PDI Reports 2013 Second Quarter Financial Results
    8. U.S. Orthopedic Biomaterials Market & Global Biomaterials Industry Reviewed by Products and Applications in New Research Reports
    9. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
    10. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
    11. Neuland Labs Reports First Quarter Fiscal Year 2014 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "Inhaled Drug Delivery (London, UK - ... This Inhaled Drug Delivery meeting will cover industry ... and much more. The Co-Chairmen are Dr Steven ... , Senior Director, Mylan. Companies participating ...
    (Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "An Introduction to ... - November 2-3, 2015)" conference to their ... a comprehensive introduction to the regulations and requirements ... will be highly interactive, using real life examples ...
    (Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
    Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
    ... (Nasdaq:,CRYO), a medical device company focused on the treatment ... its pivotal,clinical study for the treatment of atrial fibrillation. ... said, "This is a,major milestone for CryoCor, being the ... for the use of ablation for the treatment of,atrial ...
    ... Novogen Limited,s subsidiary, Marshall Edwards Inc. (Nasdaq: MSHL ), has ... made the following ... Marshall Edwards, Inc. (Nasdaq: MSHL ) today announced enrolment of ... of,phenoxodiol in women with advanced ovarian cancer resistant or refractory,to platinum-based ...
    Cached Medicine Technology:CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 2First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 4First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 5First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 6
    (Date:9/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Melissa Memorial Hospital in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
    (Date:9/3/2015)... ... , ... Dr. Robert Winchell has been appointed director of the Trauma Center ... Cornell Medical Center, effective July 27. He will serve on the faculty of Weill ... the critically injured and the development, design and operations of trauma systems. As chief, ...
    (Date:9/3/2015)... Angeles, Ca (PRWEB) , ... September 03, 2015 , ... ... is a promising and convenient test that may help patients with oropharyngeal cancer (oral ... cases in the United States are often caused by HPV infections, which have a ...
    (Date:9/3/2015)... ... ... Global Vision , the world leader in the development of innovative ... artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. , ... #F33 , Be the first to get a sneak peek of Intelligent Proofreading. Global ...
    (Date:9/3/2015)... , ... September 03, 2015 , ... ... (ACA) triggering cost increases for fully insured employer-sponsored health insurance plans, more employers ... (1,000+ employees), according to data released from the 2014 United Benefit Advisors (UBA) ...
    Breaking Medicine News(10 mins):Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
    ... Ben-Gurion University of the Negev researcher has achieved a ... mouse cells. "This study may open new therapeutic ... pre-pubertal cancer patients at risk of infertility due to ... in adult patients," explains Prof. Mahmoud Huleihel, of BGU,s ...
    ... Training basic surgical techniques on toy animals before having to ... anxious. At the same time, the use of laboratory animals ... from LIFE - the Faculty of Life Sciences at the ... known as the ,teddy laboratory, strengthens learning and the teaching ...
    ... Amanda Gardner HealthDay Reporter , MONDAY, Nov. 14 ... of the brain seem to be involved in "chemo brain," ... treatments for breast cancer. According to research in the ... areas of the brain that are involved in planning, attention ...
    ... 15 (HealthDay News) -- Brainy children are at increased risk ... study says. Researchers analyzed data from nearly 8,000 people ... education and socioeconomic status. The participants, IQ scores were checked ... illegal drugs (marijuana, cocaine, uppers, downers, LSD and heroin) was ...
    ... Steven Reinberg HealthDay Reporter , TUESDAY, Nov. 15 ... to the statin drug Zocor (simvastatin) to help lower their ... Even though niacin appeared to increase HDL cholesterol -- ... fat in the blood, it did not reduce the risk ...
    ... breakthrough in understanding what stops a common form of skin ... available to the public in five years. ... Cancer Cell , an international team of scientists led ... University,s Department of Medicine at the Alfred Hospital, has discovered ...
    Cached Medicine News:Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Breast Cancer Chemo Tied to Memory Troubles 2Health News:Breast Cancer Chemo Tied to Memory Troubles 3Health News:Smart Kids More Likely to Try Illicit Drugs as Young Adults 2Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3Health News:Stop signal discovered for skin cancer 2
    The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
    ... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
    For patient-friendly and safe capillary blood collection...
    ... a widely used screening test for determining ... oriented Dispette branded system is considered the ... stamp. No other system meets defined NCCLS/ICSH ... care. Specialized systems are also available for ...
    Medicine Products: